STOCK TITAN
  1. Home
  2. Sec-filings
  3. UTHR
  4. [Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

United Therapeutics CFO sells 10K shares

United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales. On June 15, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share and converted those options into stock.

On the same date, he sold 10,000 shares of United Therapeutics common stock in multiple open-market transactions, at weighted average prices generally in the low-to-mid $500s per share, as detailed by price ranges in the footnotes. After these transactions, he directly owned 18,876 shares of common stock. The filing states that the option exercise and subsequent sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.49M)
Approx. gross sale proceeds $5.49M
Approx. exercise cost $1.18M
Approx. pre-tax spread $4.31M
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $117.76 $1.18M
Sale Common Stock 121 $538.5233 $65K
Sale Common Stock 74 $539.4576 $40K
Sale Common Stock 45 $540.638 $24K
Sale Common Stock 240 $541.6117 $130K
Sale Common Stock 560 $543.5046 $304K
Sale Common Stock 855 $545.6344 $467K
Sale Common Stock 504 $546.5354 $275K
Sale Common Stock 465 $547.7661 $255K
Sale Common Stock 1,616 $548.6391 $887K
Sale Common Stock 800 $549.8704 $440K
Sale Common Stock 2,200 $550.8909 $1.21M
Sale Common Stock 1,144 $551.9074 $631K
Sale Common Stock 778 $553.0989 $430K
Sale Common Stock 598 $553.7629 $331K
Holdings After Transaction: Stock Option — 0 contracts (Direct); Common Stock — 18,876 shares (Direct)
Footnotes (15)
  1. F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
  2. F10. This transaction was executed in multiple trades at prices ranging from $548.27 to $549.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. F11. This transaction was executed in multiple trades at prices ranging from $549.34 to $550.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F12. This transaction was executed in multiple trades at prices ranging from $550.36 to $551.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. F13. This transaction was executed in multiple trades at prices ranging from $551.40 to $552.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. F14. This transaction was executed in multiple trades at prices ranging from $552.42 to $553.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. F15. This transaction was executed in multiple trades at prices ranging from $553.45 to $554.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F2. This transaction was executed in multiple trades at prices ranging from $537.91 to $538.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F3. This transaction was executed in multiple trades at prices ranging from $538.91 to $539.865. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. F4. This transaction was executed in multiple trades at prices ranging from $539.96 to $540.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  11. F5. This transaction was executed in multiple trades at prices ranging from $541.57 to $541.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  12. F6. This transaction was executed in multiple trades at prices ranging from $542.99 to $543.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  13. F7. This transaction was executed in multiple trades at prices ranging from $545.06 to $546.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  14. F8. This transaction was executed in multiple trades at prices ranging from $546.16 to $547.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  15. F9. This transaction was executed in multiple trades at prices ranging from $547.25 to $548.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Open-market sales of common stock on June 15, 2026
Option shares exercised 10,000 shares Stock options exercised into common stock on June 15, 2026
Option exercise price $117.76 per share Exercise price for 10,000 stock options
Post-transaction holdings 28,876 shares Common stock directly owned after reported transactions
Highest weighted average sale price $553.76 per share One of the reported weighted average sale prices for common stock
Lowest weighted average sale price $538.52 per share One of the reported weighted average sale prices for common stock
Option expiration date March 15, 2027 Expiration for the exercised stock option grant
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did United Therapeutics (UTHR) report for CFO James Edgemond?
United Therapeutics CFO James Edgemond exercised 10,000 stock options and sold 10,000 shares. The Form 4 shows a same-day option exercise and open-market sales of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

How many United Therapeutics (UTHR) shares did the CFO sell and at what prices?
The CFO sold 10,000 United Therapeutics common shares in open-market trades. The filing lists multiple transactions with weighted average sale prices in the low-to-mid $500s per share, supported by detailed price ranges in the footnotes.

What stock options did the United Therapeutics (UTHR) CFO exercise in this Form 4?
He exercised stock options covering 10,000 shares of common stock at $117.76 per share. These options, originally exercisable from March 15, 2023 and expiring March 15, 2027, were fully exercised and converted into common shares.

How many United Therapeutics (UTHR) shares does the CFO hold after these transactions?
After the reported transactions, the CFO directly owned 28,876 United Therapeutics shares. This post-transaction ownership figure is disclosed in the Form 4 as the total common stock held directly following the option exercise and sales.

Were the United Therapeutics (UTHR) CFO’s share sales discretionary or under a trading plan?
The option exercise and subsequent share sales were executed under a Rule 10b5-1 trading plan. The footnotes state the plan was entered into on October 31, 2025, indicating the transactions were pre-arranged rather than timed discretionarily.

What does the United Therapeutics (UTHR) Form 4 say about trade pricing details?
The Form 4 notes that many sales were executed in multiple trades within specified price ranges. For each such sale, the reported price is a weighted average, and the insider undertakes to provide full trade details upon request to regulators or shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES
(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET
(Street)
SILVER SPRING MARYLAND 20910
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026M(1)10,000A$117.7628,876D
Common Stock06/15/2026S(1)121D$538.5233(2)28,755D
Common Stock06/15/2026S(1)74D$539.4576(3)28,681D
Common Stock06/15/2026S(1)45D$540.638(4)28,636D
Common Stock06/15/2026S(1)240D$541.6117(5)28,396D
Common Stock06/15/2026S(1)560D$543.5046(6)27,836D
Common Stock06/15/2026S(1)855D$545.6344(7)26,981D
Common Stock06/15/2026S(1)504D$546.5354(8)26,477D
Common Stock06/15/2026S(1)465D$547.7661(9)26,012D
Common Stock06/15/2026S(1)1,616D$548.6391(10)24,396D
Common Stock06/15/2026S(1)800D$549.8704(11)23,596D
Common Stock06/15/2026S(1)2,200D$550.8909(12)21,396D
Common Stock06/15/2026S(1)1,144D$551.9074(13)20,252D
Common Stock06/15/2026S(1)778D$553.0989(14)19,474D
Common Stock06/15/2026S(1)598D$553.7629(15)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$117.7606/15/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.000.00D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $537.91 to $538.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $538.91 to $539.865. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $539.96 to $540.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $541.57 to $541.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $542.99 to $543.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $545.06 to $546.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $546.16 to $547.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $547.25 to $548.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $548.27 to $549.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $549.34 to $550.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
12. This transaction was executed in multiple trades at prices ranging from $550.36 to $551.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
13. This transaction was executed in multiple trades at prices ranging from $551.40 to $552.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
14. This transaction was executed in multiple trades at prices ranging from $552.42 to $553.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
15. This transaction was executed in multiple trades at prices ranging from $553.45 to $554.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on UTHR

Trending in the feed

Open the live feed